Instrument Inactif

Communiqués Original Source Entertainment Inc Other OTC

Actions

US6862111035

Equipement et technologie médicale avancés

Communiqués

17/09	NeuroOne® Expands U.S. Commercialization of FDA-Cleared OneRF® Trigeminal Nerve Ablation System with New Southern California Distribution Agreement	GL
27/08	NeuroOne Medical Technologies : Announces Successful Robotic-Assisted Drug Delivery Using Next-Generation StereoCED(TM) Platform	PU
12/06	NeuroOne Medical Technologies : Amendment to Quarterly Report (Form 10-Q/A)	PU
15/04	NeuroOne(R) Advances Brain Drug Delivery Platform Through Collaboration With University of Minnesota	EQ
14/04	NeuroOne(R) Medical Technologies Announces Reverse Stock Split to Regain Nasdaq Compliance	EQ
02/04	NeuroOne(R) Medical Technologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	EQ
26/03	NeuroOne(R) Successfully Completes Limited Market Release of OneRF(R) Trigeminal Nerve Ablation System	EQ
17/03	NeuroOne(R) Announces Publication of Clinical Experience With Its OneRF(R) sEEG-Guided Radiofrequency Ablation Technology	EQ
11/03	NeuroOne(R) to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference March 17, 2026 at 1:20 p.m. Eastern Time	EQ
09/03	NeuroOne(R) Issues Shareholder Letter and Provides Corporate Update	EQ
03/03	NeuroOne(R) Appoints David Wambeke as Chief Business Officer; Concurrently Completes Insider Purchase of 1 Million Shares	EQ
26/02	NeuroOne(R) to Host Virtual Investor Webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time	EQ
17/02	NeuroOne Reports Fiscal Q1 2026 Financial Results; Expects Product Revenue of At Least $10.5 Million in Fiscal Year 2026	EQ
04/02	NeuroOne(R) to Report First Quarter Fiscal Year 2026 Financial Results on Tuesday, February 17 at 8:30 a.m. Eastern Time	EQ
22/12	NeuroOne(R) Appoints Jason Mills to the Board of Directors	EQ
17/12	NeuroOne Reports Strong Fourth Quarter Fiscal 2025 Financial Results With Product Revenue Growth of 907% to $2.7 Million and 55.8% Gross Margin & Total Revenue Growth of 163% to $9.1 Million for Fiscal Year 2025	EQ
17/12	NeuroOne Medical Technologies : Annual Report for Fiscal Year Ending September 30, 2025 (Form 10-K)	PU
11/12	NeuroOne(R) to Report Fourth Quarter and Fiscal Year 2025 Financial Results on Wednesday, December 17th at 8:30 a.m. Eastern Time	EQ
09/12	NeuroOne(R) Announces Initial Successful Cases Completed With OneRF(R) Trigeminal Nerve Ablation System at the University Hospitals in Cleveland	EQ
19/11	NeuroOne(R) Announces Upcoming Industry Conference Participation	EQ
05/11	NeuroOne(R) Receives 180-Day Extension From Nasdaq to Regain Minimum Bid Price Compliance	EQ
16/10/25	NeuroOne Promotes Emily Johns to Chief Administrative Officer	EQ
14/10/25	NeuroOne(R) Bolsters Patent Portfolio With Recent Decisions From Both the U.S. Patent & Trademark Office and European Patent Office	EQ
06/10/25	NeuroOne Announces Preliminary Unaudited Product Revenue Growth of 163% to Record $9.1 Million, Invitation to Join Virtual Investor Webinar Tomorrow at 8:30 am EST	EQ
29/09/25	NeuroOne(R) Announces Virtual Investor Webinar on October 7, 2025 at 8:30 a.m. EST	EQ